• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

视网膜母细胞瘤的保眼治疗:单纯延长初始化疗或联合局部治疗。

Eye-preserving therapy in retinoblastoma: prolonged primary chemotherapy alone or combined with local therapy.

作者信息

Shin Joo Young, Kim Jeong Hun, Yu Young Suk, Khwarg Sang In, Choung Ho Kyung, Shin Hee Young, Ahn Hyo Seop

机构信息

Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Korea.

出版信息

Korean J Ophthalmol. 2010 Aug;24(4):219-24. doi: 10.3341/kjo.2010.24.4.219. Epub 2010 Aug 3.

DOI:10.3341/kjo.2010.24.4.219
PMID:20714385
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2916103/
Abstract

PURPOSE

To evaluate the efficacy of primary chemotherapy combined with local therapy in the treatment of retinoblastomas not treatable with a single therapeutic method.

METHODS

We performed a retrospective chart review of 227 patients diagnosed with retinoblastoma. Sixty-five eyes in 52 patients had tumors not treatable with a single therapeutic method and received primary chemotherapy combined with local therapy as needed.

RESULTS

Tumor control and eye salvage was achieved in 34 of the 65 eyes; the probability of ocular survival was 46.56% using the Kaplan-Meier method. Forty-three of the 65 eyes were group D or E tumors, in which tumor control and eye salvage was achieved in 16 eyes. Twenty eyes were treated with chemotherapy only, while 28 eyes received one additional modality of local therapy, and 17 eyes received two modalities of local therapy. Of the eyes treated with chemotherapy only, tumor control was achieved in 5 eyes.

CONCLUSIONS

Primary chemotherapy combined with local therapy can be effective and safe in the treatment of retinoblastomas otherwise untreatable with other therapeutic methods, such as group D and E retinoblastomas. More vigorous treatment with more local therapeutic methods combined may yield even better results.

摘要

目的

评估原发性化疗联合局部治疗在治疗无法用单一治疗方法治愈的视网膜母细胞瘤中的疗效。

方法

我们对227例诊断为视网膜母细胞瘤的患者进行了回顾性病历审查。52例患者的65只眼中有肿瘤无法用单一治疗方法治愈,并根据需要接受了原发性化疗联合局部治疗。

结果

65只眼中有34只实现了肿瘤控制和眼球挽救;使用Kaplan-Meier方法计算的眼球存活概率为46.56%。65只眼中有43只为D组或E组肿瘤,其中16只实现了肿瘤控制和眼球挽救。20只眼仅接受化疗,28只眼额外接受了一种局部治疗方式,17只眼接受了两种局部治疗方式。仅接受化疗的眼中,有5只实现了肿瘤控制。

结论

原发性化疗联合局部治疗对于其他治疗方法无法治愈的视网膜母细胞瘤(如D组和E组视网膜母细胞瘤)可能是有效且安全的。联合更多局部治疗方法进行更积极的治疗可能会产生更好的效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6db/2916103/4d5adc794732/kjo-24-219-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6db/2916103/e26ae2fb28ee/kjo-24-219-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6db/2916103/4d5adc794732/kjo-24-219-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6db/2916103/e26ae2fb28ee/kjo-24-219-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6db/2916103/4d5adc794732/kjo-24-219-g002.jpg

相似文献

1
Eye-preserving therapy in retinoblastoma: prolonged primary chemotherapy alone or combined with local therapy.视网膜母细胞瘤的保眼治疗:单纯延长初始化疗或联合局部治疗。
Korean J Ophthalmol. 2010 Aug;24(4):219-24. doi: 10.3341/kjo.2010.24.4.219. Epub 2010 Aug 3.
2
Functional results after treatment of retinoblastoma.视网膜母细胞瘤治疗后的功能结果。
J AAPOS. 2002 Apr;6(2):108-11. doi: 10.1067/mpa.2002.121451.
3
Macular retinoblastoma: evaluation of tumor control, local complications, and visual outcomes for eyes treated with chemotherapy and repetitive foveal laser ablation.黄斑区视网膜母细胞瘤:化疗联合重复黄斑中心凹激光消融治疗后眼部肿瘤控制、局部并发症及视力预后评估
Ophthalmology. 2007 Jan;114(1):162-9. doi: 10.1016/j.ophtha.2006.06.042. Epub 2006 Oct 27.
4
Clinical outcome and regression patterns of retinoblastoma treated with systemic chemoreduction and focal therapy: A prospective study.全身化疗减积联合局部治疗视网膜母细胞瘤的临床结局及消退模式:一项前瞻性研究。
Indian J Ophthalmol. 2016 Jul;64(7):524-9. doi: 10.4103/0301-4738.190143.
5
[The efficacy of large spot indirect ophthalmoscopy laser alone or combined with systemic chemotherapy in retinoblastoma therapy].[单纯大光斑间接检眼镜激光或联合全身化疗在视网膜母细胞瘤治疗中的疗效]
Zhonghua Yan Ke Za Zhi. 2016 Oct 11;52(10):745-748. doi: 10.3760/cma.j.issn.0412-4081.2016.10.006.
6
Eye-Preserving Therapies for Advanced Retinoblastoma: A Multicenter Cohort of 1678 Patients in China.保留眼球的晚期视网膜母细胞瘤治疗:中国多中心 1678 例患者队列研究。
Ophthalmology. 2022 Feb;129(2):209-219. doi: 10.1016/j.ophtha.2021.09.002. Epub 2021 Sep 15.
7
Retinoblastoma in Victoria, 1976-2000: changing management trends and outcomes.1976 - 2000年维多利亚州的视网膜母细胞瘤:管理趋势与治疗结果的变化
Clin Exp Ophthalmol. 2004 Aug;32(4):354-9. doi: 10.1111/j.1442-9071.2004.00836.x.
8
A 10-year experience of outcome in chemotherapy-treated hereditary retinoblastoma.化疗治疗遗传性视网膜母细胞瘤10年的疗效经验
Acta Ophthalmol. 2014 Aug;92(5):404-11. doi: 10.1111/aos.12282. Epub 2013 Oct 7.
9
Globe salvage treatment in group D and group E retinoblastoma.D 组和 E 组视网膜母细胞瘤的眼球保留治疗。
Rom J Ophthalmol. 2021 Jan-Mar;65(1):20-24. doi: 10.22336/rjo.2021.5.
10
Chemotherapy plus local treatment in the management of intraocular retinoblastoma.化疗联合局部治疗在眼内视网膜母细胞瘤管理中的应用
Arch Ophthalmol. 1996 Nov;114(11):1348-56. doi: 10.1001/archopht.1996.01100140548005.

引用本文的文献

1
Current Indications of Secondary Enucleation in Retinoblastoma Management: A Position Paper on Behalf of the European Retinoblastoma Group (EURbG).视网膜母细胞瘤治疗中二次眼球摘除术的当前指征:代表欧洲视网膜母细胞瘤研究组(EURbG)发布的立场文件
Cancers (Basel). 2021 Jul 6;13(14):3392. doi: 10.3390/cancers13143392.
2
Effect of Intravenous Chemotherapy Regimen on Globe Salvage Success Rates for Retinoblastoma Based on Disease Class-A Meta-Analysis.基于疾病分类的静脉化疗方案对视网膜母细胞瘤眼球挽救成功率的影响——一项荟萃分析
Cancers (Basel). 2021 May 6;13(9):2216. doi: 10.3390/cancers13092216.
3
Intravenous Chemotherapy for Retinoblastoma in the Era of Intravitreal Chemotherapy: A Systematic Review.

本文引用的文献

1
Chemoreduction for group E retinoblastoma: comparison of chemoreduction alone versus chemoreduction plus low-dose external radiotherapy in 76 eyes.E 组视网膜母细胞瘤的化学减容:76 只眼单纯化学减容与化学减容加低剂量外照射放疗的比较
Ophthalmology. 2009 Mar;116(3):544-551.e1. doi: 10.1016/j.ophtha.2008.10.014. Epub 2009 Jan 20.
2
The success of primary chemotherapy for group D heritable retinoblastoma.D组遗传性视网膜母细胞瘤的原发性化疗成效
Br J Ophthalmol. 2009 Jul;93(7):887-90. doi: 10.1136/bjo.2008.142679. Epub 2008 Aug 14.
3
Intraocular retinoblastoma: the case for a new group classification.
玻璃体内化疗时代视网膜母细胞瘤的静脉化疗:一项系统评价
Ocul Oncol Pathol. 2021 Mar;7(2):142-148. doi: 10.1159/000510506. Epub 2020 Dec 16.
4
Globe salvage treatment in group D and group E retinoblastoma.D 组和 E 组视网膜母细胞瘤的眼球保留治疗。
Rom J Ophthalmol. 2021 Jan-Mar;65(1):20-24. doi: 10.22336/rjo.2021.5.
5
Development of New Solitary Retinoblastoma Tumors during and after Chemotherapy.化疗期间和化疗后新发孤立性视网膜母细胞瘤。
Korean J Ophthalmol. 2021 Feb;35(1):73-79. doi: 10.3341/kjo.2020.0115. Epub 2021 Feb 2.
6
Comparison between intravenous chemotherapy and intra-arterial chemotherapy for retinoblastoma: a meta-analysis.静脉化疗与眼内动脉化疗治疗视网膜母细胞瘤的比较:一项荟萃分析。
BMC Cancer. 2018 Apr 27;18(1):486. doi: 10.1186/s12885-018-4406-6.
7
Safety and efficacy of posterior sub-Tenon's carboplatin injection versus intravitreal melphalan therapy in the management of retinoblastoma with secondary vitreous seeds.后Tenon囊下注射卡铂与玻璃体内注射美法仑治疗伴有继发性玻璃体种植的视网膜母细胞瘤的安全性和有效性
Int J Ophthalmol. 2018 Mar 18;11(3):445-455. doi: 10.18240/ijo.2018.03.15. eCollection 2018.
8
Unusually very late-onset new growth of intraocular retinoblastoma: A case report and review of literature.极罕见的迟发性眼内视网膜母细胞瘤新发病例:一例报告并文献复习
Am J Ophthalmol Case Rep. 2016 Dec 28;5:130-133. doi: 10.1016/j.ajoc.2016.12.013. eCollection 2017 Apr.
9
Pharmacokinetics, Tissue Localization, Toxicity, and Treatment Efficacy in the First Small Animal (Rabbit) Model of Intra-Arterial Chemotherapy for Retinoblastoma.眼内动脉化疗治疗视网膜母细胞瘤的首例小动物(兔)模型的药代动力学、组织定位、毒性和疗效。
Invest Ophthalmol Vis Sci. 2018 Jan 1;59(1):446-454. doi: 10.1167/iovs.17-22302.
10
An international survey of classification and treatment choices for group D retinoblastoma.一项关于D组视网膜母细胞瘤分类与治疗选择的国际调查。
Int J Ophthalmol. 2017 Jun 18;10(6):961-967. doi: 10.18240/ijo.2017.06.20. eCollection 2017.
眼内视网膜母细胞瘤:一种新的分组分类方法
Ophthalmol Clin North Am. 2005 Mar;18(1):41-53, viii. doi: 10.1016/j.ohc.2004.11.003.
4
Causes of chemoreduction failure in retinoblastoma and analysis of associated factors leading to eventual treatment with external beam radiotherapy and enucleation.视网膜母细胞瘤中化学减灭术失败的原因及导致最终采用外照射放疗和眼球摘除术治疗的相关因素分析。
Ophthalmology. 2004 Oct;111(10):1917-24. doi: 10.1016/j.ophtha.2004.04.016.
5
Chemoreduction for retinoblastoma. Analysis of tumor control and risks for recurrence in 457 tumors.视网膜母细胞瘤的化学减灭法。457例肿瘤的肿瘤控制及复发风险分析。
Am J Ophthalmol. 2004 Sep;138(3):329-37. doi: 10.1016/j.ajo.2004.04.032.
6
Practical approach to management of retinoblastoma.视网膜母细胞瘤管理的实用方法。
Arch Ophthalmol. 2004 May;122(5):729-35. doi: 10.1001/archopht.122.5.729.
7
The evaluation and current concept of retinoblastoma therapy.视网膜母细胞瘤治疗的评估与当前理念
Trans Am Acad Ophthalmol Otolaryngol. 1963 Mar-Apr;67:164-72.
8
Clinical result of prolonged primary chemotherapy in retinoblastoma patients.视网膜母细胞瘤患者长期初级化疗的临床结果
Korean J Ophthalmol. 2003 Jun;17(1):35-43. doi: 10.3341/kjo.2003.17.1.35.
9
Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation.视网膜母细胞瘤的化学减灭术联合局部治疗:预测需行外照射放疗或眼球摘除术治疗的因素
Am J Ophthalmol. 2002 May;133(5):657-64. doi: 10.1016/s0002-9394(02)01348-x.
10
Combined chemotherapy and local treatment in the management of intraocular retinoblastoma.联合化疗与局部治疗在眼内视网膜母细胞瘤治疗中的应用
Med Pediatr Oncol. 2002 Jun;38(6):411-5. doi: 10.1002/mpo.1355.